Evidence map›Paper›PMID 39640071›Full record

ArticleCancer innovation2025

Expression pattern and prognostic significance of aldehyde dehydrogenase 2 in lung adenocarcinoma as a potential predictor of immunotherapy efficacy.

Silvia Baldari, Annalisa Antonini, Giuliana Di Rocco, Gabriele Toietta

Abstract read
In one paragraph

Article in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Silvia BaldariTumor Immunology and Immunotherapy Unit IRCCS Regina Elena National Cancer Institute Rome Italy.ORCID 0000-0001-7982-9468
Annalisa AntoniniTumor Immunology and Immunotherapy Unit IRCCS Regina Elena National Cancer Institute Rome Italy.ORCID 0009-0004-9693-6037
Giuliana Di RoccoUnit of Cellular Networks and Molecular Therapeutic Targets IRCCS Regina Elena National Cancer Institute Rome Italy.ORCID 0000-0003-1210-6008
Gabriele ToiettaTumor Immunology and Immunotherapy Unit IRCCS Regina Elena National Cancer Institute Rome Italy.ORCID 0000-0003-4182-2468

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence of alcohol-associated cancers is higher within Asian populations having an increased prevalence of an inactivating mutation in aldehyde dehydrogenase 2 ( Methods: We performed a comprehensive bioinformatic analysis of multi-omics data available in public databases to elucidate the role of ALDH2 in lung adenocarcinoma (LUAD). Results: Transcriptional and proteomic data indicate a substantial pulmonary expression of ALDH2, which is functional for the metabolism of alcohol diffused from the bronchial circulation. ALDH2 expression is higher in healthy lung tissue than in LUAD and inhibits cell cycle, apoptosis, and epithelial-mesenchymal transition pathways. Moreover, low Conclusions: A better understanding of the role of ALDH2 in lung tumor progression and immune infiltration might support its potential use as a prognostic marker and therapeutic target for improving immunotherapeutic response.

Indexed as

acetaldehydealcoholaldehyde dehydrogenaseethanol metabolismimmunotherapylung adenocarcinomamitochondriars671 polymorphism (Glu504Lys) of aldehyde dehydrogenase 2

Identifiers

PMID39640071
PMCPMC11620833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.